MUC5AC and chronic obstructive pulmonary disease: After treatment with LQZS or CAM, we found that the therapy could significantly improve the MVV, reduce histopathological injury, and inhibit MUC5AC mRNA transcription and protein synthesis in lung tissues of COPD.